中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 6
Jun.  2012
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2012  >  28(6): 469-473

Review of recent research progress in correlating HBV genotypes with efficacy of antiviral treatments

  • Published Date: 2012-06-20
    Abstract
  • Hepatitis B is one of the most prevalent infectious diseases worldwide.Moreover, chronic hepatitis B virus (HBV) infection is strongly associated with subsequent development of life-threatening hepatic diseases, such as heptocellular carcinoma, decompensated cirrhosis, and advanced fibrosis.Extensive studies of the various HBV genotypes have uncovered a close correlated with clinical factors, which may help to design and implement effective therapeutic strategies for treating infections with the different genotypes.Since antivirus therapy remains the main treatment for hepatitis B, research studies have focused on determining the relations between the various HBV genotypes and efficacy of the currently available antiviral drugs.In this review, we systematically discuss the recent findings from the literature on HBV genotype correlations with efficacy of antivirus treatment.

     

    • FullText(HTML)
    • References(50)
  • [1]Norder H, Courouce AM, Magnius LO.Complete genomes, phylo-genetic relatedness, and structural proteins of six strains of the hepa-titis B virus, four of which represent two new genotypes[J].Virolo-gy, 1994, 198 (2) :489-503.
    [2]Okamoto H, Tsuda F, Sakugawa H, et al.Typing hepatitis B virusby homologv in nucleotide sequence:comparison of surface antigensubtypes[J].J Gen Virol, 1988, 69 (10) :2575-2583.
    [3]Stuyver L, De Gendt S, Van Geyt C, et al.A new genotype of hep-atitis B virus:complete genome and phylogenetic relatedness[J].JGen Virol, 2000, 81 (1) :67-74.
    [4]Arankalle VA, Gandhe SS, Borkakoty BJ, et al.A novel HBV re-combinant (genotype I) similar to Vietnam/Laos in a primitive tribein eastern India[J].J Viral Hepatol, 2010, 17 (7) :501-510.
    [5]Fuminaka S, Anuchit C, Etsuro O, et al.Hepatitis B virus geno-types and clinical manifestation among hepatitis B carriers in Thai-land[J].J Gastroenterol Hepatol, 2002, 17 (6) :671-676.
    [6]Mota A, Guedes F, Areias J, et al.Epidemiological study of geno-types of hepatitis B virus in northern Portugal[J].J Med Virol, 2009, 81 (7) :1170-1176.
    [7]Baig S, Siddiqui AA, Ahmed W, et al.The association of complexliver disorders with HBV genotypes prevalent in Pakistan[J].VirolJ, 2007, 27 (4) :128.
    [8]Tonetto PA, Goncales NS, Fais VC, et al.Hepatitis B virus:mo-lecular genotypes and HBeAg serological status among HBV-infec-ted patients in the southeast of Brazil[J].BMC Infect Dis, 2009, 8 (9) :149.
    [9]Madan K, Batra Y, Sreenivas V, et al.HBV genotypes in India:do they influence disease severity?[J].Hepatol Res, 2009, 39 (2) :157-163.
    [10] 温志立, 邓青, 张华, 等.采用多对型特异性引物巢式PCR法研究江西省HBV基因型分布及其临床相关性[J].中华微生物学和免疫学杂志, 2009, 29 (2) :175-176.
    [11]Niu J, He S, Su C, et al.Variability of the S gene of hepatitis B vi-rus in southeastern China[J].Arch Virol, 2010, 155 (12) :1951-1957.
    [12]Sherman M.Risk of hepatocellular carcinoma in hepatitis B andprevention through treatment[J].Cleve Clin J Med, 2009, 76 (Suppl 3) :6-9.
    [13]Pujol FH, Navas MC, Hainaut P, et al.Worldwide genetic diversi-ty of HBV genotypes and risk of hepatocellular carcinoma[J].Cancer Lett, 2009, 286 (1) :80-88.
    [14]Liang TJ, Mok KT, Liu SI, et al.Hepatitis B genotype C correlatedwith poor Surgical outcomes for hepatocellular carcinoma[J].J AmColl Surg, 2010, 211 (5) :580-586.
    [15]Hassan ZK, Hafez MM, Mansor TM, et al.Occult HBV infectionamong Egyptian hepatocellular carcinoma patients[J].Virol J, 2011, 8 (1) :90.
    [16]Lin CL, Kao JH.The clinical implications of hepatitis B virus geno-type:Recent advances[J].J Gastroenterol Hepatol, 2011, 26 (Suppl 1) :123-130.
    [17]Ali L, Idrees M, Ali M, et al.An overview of treatment responserates to various anti-viral drugs in Pakistani hepatitis B virus infec-ted patients[J].Virol J, 2011, 15 (8) :20.
    [18]Raimondi, Sara M, Patrick B, et al.Is response to antiviral treat-ment influenced by hepatitis B virus genotype?[J].J Hepatol, 2010, 52 (3) :441-449.
    [19]Zhu CT, Dong CL.Characteristics of general distribution of hepati-tis B virus genotypes in China[J].Hepatobiliary Pancreat Dis Int, 2009, 8 (4) :397-401.
    [20]于秀艳, 汪杰, 刘鹏, 等.乙型肝炎病毒基因型与干扰素抗病毒治疗相关性的探讨[J].中国实验诊断学, 2009, 13 (1) :115-116.
    [21]蔡艳萍, 黄元成, 张美珍, 等.乙肝病毒基因型对武汉地区慢性乙型肝炎患者干扰素α-2b疗效的影响[J].中西医结合肝病杂志, 2010, 20 (2) :83-85.
    [22]肖扬, 周岳进, 郑金莉, 等.乙型肝炎病毒基因型和早期病毒学应答对干扰素α-2b治疗慢性乙型肝炎疗效的预测价值[J].实用肝脏病杂志, 2009, 12 (1) :23-24, 80.
    [23]Zhao H, Kurbanov F, Wan MB, et al.Genotype B and younger pa-tient age associated with better response to low-dose therapy:a tri-al with pegylated/nonpegylated interferon-alpha-2b for hepatitisB e antigen-positive patients with chronic hepatitis B in China[J].Clin Infect Dis, 2007, 44 (4) :541-548.
    [24]Alfaresi M, Elkoush A, Alshehhi A, et al.Hepatitis B virus geno-types and precore and core mutants in UAE patients[J].Virol J, 2010, 15 (7) :160.
    [25]Antaki N, Haffar S, Ali Deeb S, et al.High prevalence of HBVgenotype D in Syria and the clinical characteristics of hepatitis B eantigen-negative chronic hepatitis B[J].Epidemiol Infect, 2010, 138 (1) :40-44.
    [26]Sharma S, Sharma B, Singla B, et al.Clinical significance of geno-types and precore/basal core promoter mutations in HBV relatedchronic liver disease patients in North India[J].Dig Dis Sci, 2010, 55 (3) :794-802.
    [27]Hou J, Schilling R, Janssen HL, et al.Genetic characteristics ofhepatitis B virus genotypes as a factor for interferon-inducedHBeAg clearance[J].J Med Virol, 2007, 79 (8) :1055-1063.
    [28]Senturk H, Baysal B, Tahan V, et al.Long-term effect of interferontherapy in patients with HBeAg positive chronic hepatitis B infection[J].Dig Dis Sci, 2011, 56 (1) :208-212.
    [29]Perrillo R.Benefits and risks of interferon therapy for hepatitis B[J].Hepatology, 2009, 49 (5 Suppl) :103-111.
    [30]沈建坤, 侯金林, 潘兴南, 等.HBV基因型与聚乙二醇干扰素疗效关系及病理变化[J].南方医科大学学报, 2008, 28 (7) :1217-1222.
    [31]Bonino F, Marcellin P, Lau GKK, et al.Predicting response topeginterferonα-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B[J].Gut, 2007, 56 (5) :699-705.
    [32]Flink HJ, van Zonneveld M, Hansen BE.et al.Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitise B:HBsAg loss is associated with HBV genotype[J].Am J Gastroen-terol, 2006, 101 (2) :297-303.
    [33]Buster EH, Hansen BE, Lau GK, et al.Factors that predict re-sponse of patients with hepatitis B e antigen-positive chronic hepa-titis B to peginterferon-alfa[J].Gastro-Enterology, 2009, 137 (6) :2002-2009.
    [34]Moucari R, Martinot-Peignoux M, Mackiewicz V, et al.Influenceof genotype on hepatitis B surface antigen kinetics in hepatitis B eantigen-negative patients treated with pegylated interferon-al-pha2a[J].Antivir Ther, 2009, 14 (8) :1183-1188.
    [35]周冬生, 罗光汉, 江建宁, 等.B、C基因型与拉米夫定抗HBV疗效的比较[J].中国实用医药, 2008, 3 (13) :13-14.
    [36]Enomoto M, Tamori A, Nishiguchi S.Hepatitis B virus genotypesand response to antiviral therapy[J].Clin Lab, 2006, 52 (1-2) :43-47.
    [37]王芳, 郑岚.乙型肝炎病毒基因型与干扰素及拉米夫定抗病毒治疗相关性的探讨[J].中国医药导报, 2008, 5 (17) :30-31.
    [38]Palumbo E.Hepatitis B genotypes and response to antiviral therapy:a review[J].Am J Ther, 2007, 14 (3) :306-309.
    [39]Jardi R, Rodriguez-Frias F, Schaper M, et al.Analysis of hepati-tis B genotype changes in chronic hepatitis B infection:Influence ofantiviral therapy[J].J Hepatol, 2008, 49 (5) :695-701.
    [40]Zalewska M, Domagaa M, Simon K, et al.Hepatitis B virus geno-types and the response to lamivudine therapy[J].Pol Arch MedWewn, 2005, 114 (6) :1190-1199.
    [41]赵先胜.HBV不同基因与替比夫定抗病毒疗效关系探讨[J].海峡药学, 2010, 22 (5) :140-141.
    [42]刘兴, 周陶友, 白浪, 等.HBV基因型和阿德福韦酯疗效之间关系的初步研究[J].华西医学, 2008, 23 (3) :533-535.
    [43] 卢建溪, 王强, 陈文思, 等.阿德福韦酯抗病毒疗效与乙型肝炎病毒基因型的关系[J].中华生物医学工程杂志, 2009, 15 (3) :189-193.
    [44]胡章勇, 杨军, 许颖, 等.阿德福韦酯治疗HBeAg阴性慢性乙型肝炎疗效与HBV基因型的关系[J].传染病信息, 2009, 22 (4) :219-221.
    [45]Buti M, Elefsiniotis I, Jardi R, et al.Viral genotype and baseline loadpredict the response to adefovir treatment in lamivudine-resistant chro-nic hepatitis B patients[J].Hepatol, 2007, 47 (3) :366-372.
    [46]Ai-Zhong, Hui Deng, Chung Yang, et al.Hepatitis B virus geno-type-associated variability in antiviral response to adefovir dipivoxiltherapy in Chinese Han Population[J].Tohoku J Exp Med, 2008, 216 (3) :205-211.
    [47]李世波, 丁贤君, 李绍佐.乙型肝炎病毒基因型与阿德福韦酯治疗效应的关系[J].浙江中西医结合杂志, 2007, 17 (9) :532-534.
    [48]徐严, 张永贵, 季尚玮, 等.乙型肝炎病毒基因型检测的临床意义[J].中国实验诊断学, 2010, 14 (1) :61-63.
    [49] 徐严, 王江滨, 徐杰, 等.恩替卡韦治疗104例乙型肝炎肝硬化患者96周的疗效观察[J].中华肝脏病杂志, 2010, 18 (2) :109-112.
    [50]Gish RG, Chang TT, Lai CL, et al.Loss of HBsAg antigen duringtreatment with entecavir or lamivudine in nucleoside-nave HBeAg-positive patients with chronic hepatitis B[J].J Viral Hepat, 2010, 17 (1) :16-22.
    • Relative Articles

  • Relative Articles

    [1]Liangying GAN, Li ZUO. Micro-elimination of hepatitis C virus infection in the hemodialysis population[J]. Journal of Clinical Hepatology, 2024, 40(4): 659-664. doi: 10.12449/JCH240403
    [2]Yu WANG, Wenge XING, Zhongfu LIU, Cong JIN. Advances in laboratory testing methods and strategies for hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2024, 40(4): 672-678. doi: 10.12449/JCH240405
    [3]Li ZHANG, Peng HU. Hepatitis C virus infection and organ transplantation[J]. Journal of Clinical Hepatology, 2024, 40(4): 665-671. doi: 10.12449/JCH240404
    [4]Peng MiLin, Xiao XinQiang, Jiang YongFang, Tian Yi, Xu Yun, Zhang Min, Wang WenLong, Peng Feng, Gong GuoZhong. Preliminary study on effect of hepatitis C virus nonstructural protein 5A on HIV LTR[J]. Journal of Clinical Hepatology, 2014, 30(2): 136-140. doi: 10.3969/j.issn.1001-5256.2014.02.010
    [5]Zhu FuSheng, Qin YuJie, Cheng ZhenJiang, Jiang PeiRong, Zhang LingHui. The impact of HBV/HCV coinfection on HBV DNA levels and the severity of liver diseases in HBV-infected patients undergoing hemodialysis[J]. Journal of Clinical Hepatology, 2013, 29(2): 136-137+141.
    [6]Wang YuMing, Cheng Lin. Recent perspectives of Chinese medicine-based therapy for hepatitis B and C virus infection[J]. Journal of Clinical Hepatology, 2012, 28(11): 872-876.
    [7]Nie HongMing, Chen JianJie, Dong HuiLin, Yang YuQi, Wang ChengBao, Li HongDing, Chen YiYun, Gao YueQiu. Analysis of clinical characteristics of the infection of HCV genotype 1 and non-genotype 1 in China[J]. Journal of Clinical Hepatology, 2012, 28(6): 439-442.
    [8]Wang Yu, Zhang Ying, Jia ZhanSheng. Recent treatment advances for hepatitis C virus-related mixed cryoglobulinemia[J]. Journal of Clinical Hepatology, 2012, 28(8): 628-632.
    [9]Yin Xiao, Wen Bo, Tan WenJie. Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 32-35.
    [10]Tian Di, Xu XiaoYuan. Treatment of hepatitis C virus infection in HIV/HCV co-infected patients[J]. Journal of Clinical Hepatology, 2011, 27(5): 540-544.
    [11]Gao LuHua, Nie QingHe. Detection of hepatitis C virus in the supernatant of human placenta trophoblastic cells and cell lysates[J]. Journal of Clinical Hepatology, 2011, 27(12): 1296-1300.
    [12]Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.
    [13]Yan Yan, Xiu BingShui, Yin JiMing, Zhang HeQiu, Li Zhuo. Evaluation of cross-reactive antibody response to hypervariable region 1 of hepatitis C virus[J]. Journal of Clinical Hepatology, 2011, 27(8): 818-820.
    [14]Qi ZhongTian. Hepatitis C virus infection and its therapeutic drugs[J]. Journal of Clinical Hepatology, 2011, 27(1): 15-18+27.
    [15]Yang RuiFeng, Wei Lai. Detection of hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 1-7.
    [16]Jiang XiaoHua, Liu LingLing, Lei Chuang, Zhou QingPing. Effects of hepatitis C virus genotype 1b core protein on the gene expressions of Bax and Bcl-2 in HepG2 cells[J]. Journal of Clinical Hepatology, 2011, 27(5): 511-514.
    [17]Sun MengNing, Lan HaiYun, Ma Yu, Zhao Ya, Lu: Xin, Yang Jing, Lei YingFeng, Yao Min, Kang Jian, Zhao MingGao, Wang AiQin, Yin Wen. Generation of conditionally controlled transgenic mice expressing hepatitis C virus NS3/4A protease[J]. Journal of Clinical Hepatology, 2011, 27(1): 76-80.
    [18]Cheng Ling, Hong GuoHu, Guo Yan, Mao Qing. Prediction of HLA-DRB1*0311/0401 in recognizing epitopes of HCV Core protein of different genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 61-64.
    [19]Wen Ming, Xiao XinQiang, Gong GuoZhong. Hepatitis C virus NS5A protein stimulates TLR4 expression[J]. Journal of Clinical Hepatology, 2011, 27(1): 49-52.
    [20]Chen LiDong, Cheng Jun, Hong Yuan, Zhang LianFeng, Han Li, Guo Jiang. Construction of the prokaryotic expression vector of NS5ATP4A gene and its expression[J]. Journal of Clinical Hepatology, 2010, 26(4): 371-373.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.2 %FULLTEXT: 2.2 %META: 81.5 %META: 81.5 %PDF: 16.3 %PDF: 16.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.3 %其他: 3.3 %Seattle: 0.1 %Seattle: 0.1 %[]: 0.3 %[]: 0.3 %上海: 7.9 %上海: 7.9 %中山: 0.1 %中山: 0.1 %佛山: 0.3 %佛山: 0.3 %兰州: 0.6 %兰州: 0.6 %北京: 0.9 %北京: 0.9 %南京: 1.0 %南京: 1.0 %南宁: 0.1 %南宁: 0.1 %南昌: 0.3 %南昌: 0.3 %南通: 0.4 %南通: 0.4 %台州: 0.6 %台州: 0.6 %吉林: 2.8 %吉林: 2.8 %哥伦布: 0.1 %哥伦布: 0.1 %嘉兴: 0.3 %嘉兴: 0.3 %大连: 0.1 %大连: 0.1 %天津: 0.3 %天津: 0.3 %太原: 0.3 %太原: 0.3 %宁波: 0.3 %宁波: 0.3 %广州: 4.6 %广州: 4.6 %张家口: 0.7 %张家口: 0.7 %徐州: 0.4 %徐州: 0.4 %成都: 1.5 %成都: 1.5 %无锡: 0.7 %无锡: 0.7 %晋中: 0.1 %晋中: 0.1 %朝阳: 0.4 %朝阳: 0.4 %杭州: 1.2 %杭州: 1.2 %柳州: 0.4 %柳州: 0.4 %桂林: 0.6 %桂林: 0.6 %武汉: 1.3 %武汉: 1.3 %池州: 0.1 %池州: 0.1 %沈阳: 0.7 %沈阳: 0.7 %济南: 1.0 %济南: 1.0 %深圳: 1.5 %深圳: 1.5 %湖州: 0.3 %湖州: 0.3 %烟台: 0.1 %烟台: 0.1 %玉林: 0.1 %玉林: 0.1 %石家庄: 2.1 %石家庄: 2.1 %福州: 0.4 %福州: 0.4 %纽约: 0.1 %纽约: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %聊城: 0.1 %聊城: 0.1 %芒廷维尤: 33.9 %芒廷维尤: 33.9 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.4 %苏州: 0.4 %莫斯科: 0.4 %莫斯科: 0.4 %衢州: 0.1 %衢州: 0.1 %襄阳: 0.3 %襄阳: 0.3 %西宁: 18.4 %西宁: 18.4 %西安: 1.3 %西安: 1.3 %郑州: 0.4 %郑州: 0.4 %重庆: 1.5 %重庆: 1.5 %金华: 0.1 %金华: 0.1 %铁岭: 0.1 %铁岭: 0.1 %长春: 1.3 %长春: 1.3 %长沙: 0.6 %长沙: 0.6 %长治: 0.3 %长治: 0.3 %阳江: 0.4 %阳江: 0.4 %黄石: 0.1 %黄石: 0.1 %其他Seattle[]上海中山佛山兰州北京南京南宁南昌南通台州吉林哥伦布嘉兴大连天津太原宁波广州张家口徐州成都无锡晋中朝阳杭州柳州桂林武汉池州沈阳济南深圳湖州烟台玉林石家庄福州纽约美国伊利诺斯芝加哥聊城芒廷维尤芝加哥苏州莫斯科衢州襄阳西宁西安郑州重庆金华铁岭长春长沙长治阳江黄石

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3220) PDF downloads(654) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2784]YesterdayPV[4482]TodayIP[1204]TodayPV[1942]Online[189]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return